Purchase this article with an account.
AV Kotecha, S Teich, I Eliasoph; Purtscher-like Retinopathy Associated with Gemcitabine Therapy . Invest. Ophthalmol. Vis. Sci. 2002;43(13):523.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To research the association between Purtscher-like retinopathy and gemcitabine therapy. Methods: Case report and literature review. Results: A 75 year-old Caucasian female, status post Whipple procedure for pancreatic carcinoma, noted a sudden onset of blurred vision with scotomata in both eyes shortly after receiving an intravenous infusion of gemcitabine therapy. She had initiated gemcitabine therapy one year prior to the onset of her visual symptoms. Best corrected Snellen visual acuity was 20/30 OD and 20/100 OS with scotomata on Amsler grid OU. Ophthalmoscopy revealed evidence of precapillary arteriolar occlusions with many cotton wool spots, exudates, and intraretinal blot and flame shaped hemorrhages consistent with Purtscher-like retinopathy. Macular edema was present in both eyes(OS ≷ OD). Fluorescein angiography confirmed these findings. The vision and retinopathy began to improve one month after initial presentation and after discontinuation of gemcitabine therapy. Two months after presentation the visual acuity had improved to 20/25 OU, with marked regression of retinopathy in both eyes. Medical evaluation of this patient revealed no evidence of pancreatitis, coagulopathy, systemic vasculitis, renal disease, or other etiologies commonly associated with Purtscher-like retinopathy or vaso-occlusive disorders. The patient's vision and ocular findings have remained stable for one year following initial presentation. Conclusion: This is the second reported case of Purtscher-like retinopathy associated with gemcitabine therapy, and suggests a possible caustive role that patients and clinicians should be aware of. We are intrigued by the possibility of a common etiology with the hemolytic-uremic syndrome, which has been caused by gemcitabine and other chemically similar agents.
This PDF is available to Subscribers Only